Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 6/20 | 0.49 |
| ▸ | HSPA2 | P54652 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 6/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620163 | 0.90 | HSPA5 (0.49) | HSPA5HSPA2CTSLCTSSCTSB | |
| SCHEMBL7463889 | 0.88 | CTSL (0.49) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL6927425 | 0.87 | CTSL (0.55) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL7467592 | 0.87 | TAS1R3 (0.49) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL7806106 | 0.85 | HSPA5 (0.49) | HSPA5HSPA2CTSLCTSSCTSB | |
| SCHEMBL7813672 | 0.85 | HSPA5 (0.49) | HSPA5HSPA2CTSLCTSSCTSB | |
| SCHEMBL7467469 | 0.85 | CTSL (0.47) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL7470718 | 0.85 | CTSL (0.51) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL7467318 | 0.85 | CTSL (0.53) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL7464820 | 0.85 | CTSL (0.47) | CTSLCTSSCTSBCTSKCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | claimed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | HSPA5 866/4885HSPA2 1923/4885CTSL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.